Taken together, our results showed that HBXIP-overexpressing NSCLC cells activated MAPK/ERK signaling, indicating that HBXIP may be a potential therapeutic target for NSCLC treatment. This evidence concerns the gene LAMTOR5 and non-small cell lung carcinoma.